StockData
Cerenome, Inc. logo

Cerenome, Inc. (CNSY) company profile

CNSYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/3071% below fair value
$0.71+0.08 (+12.14%)

Close on Nov 18, 2026Market cap $5.36MP/E –Yield –

About Cerenome

Pharmaceutical Preparations, SIC 2834

Plus Therapeutics, Inc. is a United States healthcare company focused on the development and commercialization of precision diagnostics and targeted radiotherapeutics for central nervous system cancers. Its clinical-stage pipeline features targeted radiopharmaceuticals intended to deliver radiation therapy directly to tumors, along with diagnostic solutions such as the CNSide platform and test designed for cerebrospinal fluid tumor cell enumeration, immunocytochemistry, fluorescence in situ hybridization, and next-generation sequencing. The company serves the medical and oncology sectors, targeting patients suffering from difficult-to-treat central nervous system cancers and conditions including leptomeningeal metastases.

The company operates within the United States, maintaining corporate facilities and conducting its core clinical and operational activities domestically. Its principal executive offices and headquarters are located in Houston, Texas. Beyond its domestic presence, the provided text does not report any international facilities, clinical sites, or physical retail locations.

Summary of the business section of Cerenome's latest annual report, written by StockData.

Company profile

Company

Legal name
Cerenome, Inc.
Founded
1996
Headquarters
Houston, TX
Address
6420 Levit Green Boulevard, Suite 310 77021
Phone
(737) 255-7194
Employees
28, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BDO USA P.C., Austin, Texas

Stock & identifiers

Ticker
CNSY
Former tickers
PSTV until Aug 4, 2026; CYTX until Aug 15, 2019
Exchange
Nasdaq
IPO date
Jul 11, 2001
Shares outstanding
8M, Aug 5, 2026
Public float
$31.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-25 reverse, Apr 2, 2026; 1-for-15 reverse, May 1, 2023; 1-for-50 reverse, Aug 6, 2019; 1-for-10 reverse, May 24, 2018; 1-for-15 reverse, May 12, 2016
SEC CIK
1095981
CUSIP
72941H806
ISIN
US72941H8060
FIGI
BBG000C1Z086
Share class FIGI
BBG001SFQL35
LEI
549300XD2PHUC73HMY31
EIN
33-0827593

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ronald Asbury AndrewsChief Business Officer, Director1,843
Marc H. HedrickChief Executive Officer, Director105,714
Andrew John Hugh MacIntyre SimsChief Financial Officer12,926
Eric Joseph DanielsChief Development Officer0
Howard ClowesDirector2,902
Kyle GuseDirector1,843
Richard J. HawkinsDirector2,450
Es-Johansson An vanDirector1,843
Robert P. LenkDirector139,327
Greg PetersenDirector48,921

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$5.57M$4.73M$1.63M$11–
FY2024$1.26M$1.64M$907.03K$24–
FY2023$1.13M$1.57M$1.21M$37–
FY2022$954.65K$1.64M$1.08M$30–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 28 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 1, 2026Name changeName changed from PLUS THERAPEUTICS, INC. to Cerenome, Inc.
Jul 18, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 6, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 23, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 19, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 15, 2025Late filingNotification of late filing
Sep 6, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 14, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 28, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 27, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 26, 2020DelistingNotice of delisting from exchange (Form 25)
Aug 21, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 14, 2019Late filingNotification of late filing
Aug 2, 2019Name changeName changed from CYTORI THERAPEUTICS, INC. to PLUS THERAPEUTICS, INC.
Apr 30, 2019Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 27, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 17, 2018DelistingNotice of delisting from exchange (Form 25)
Aug 31, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 7, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 28, 2017ListingRegistration of securities on an exchange (Form 8-A)
Sep 8, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 15, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 14, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 10, 2016ListingRegistration of securities on an exchange (Form 8-A)
Feb 4, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 29, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 7, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 5, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 26, 2014Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 31, 2014Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)

See a number that looks wrong?